Scientific Impact Recognition Award: Molecular breast imaging: a review of the Mayo Clinic experience.
BACKGROUND
Molecular breast imaging (MBI) depicts functional uptake of targeted radiotracers in the breast using dedicated gamma cameras.


METHODS
MBI studies were performed under several institutional protocols evaluating the use of MBI in screening and diagnosis.


RESULTS
By using a single-head system, sensitivity for breast cancer detection was 85% (57 of 67) overall and 29% for tumors 5 mm or less in diameter. Sensitivity improved to 91% (117 of 128) overall and 69% for tumors 5 mm or less using a dual-head system. In 650 high-risk patients undergoing breast cancer screening, MBI detected 7 cancers, 5 of which were missed on mammography. In 24 of 149 (16%) breast cancer patients MBI detected additional disease not seen on mammography. The sensitivity of MBI was 88% (83 of 94) for invasive ductal carcinoma, 79% (23 of 29) for invasive lobular carcinoma, and 89% (25 of 28) for ductal carcinoma in situ.


CONCLUSIONS
MBI can detect invasive ductal carcinoma, ductal carcinoma in situ, and invasive lobular carcinoma. It has a promising role in evaluating the extent of disease and multifocal disease in the breast for surgical treatment planning.
Hruska
Carrie B
CB
Department of Nuclear Medicine, Mayo Clinic, Rochester, MN 55905, USA.
Boughey
Judy C
JC
Phillips
Stephen W
SW
Rhodes
Deborah J
DJ
Wahner-Roedler
Dietlind L
DL
Whaley
Dana H
DH
Degnim
Amy C
AC
O'Connor
Michael K
MK
D000328:Adult; D001943:Breast Neoplasms / Q000000981:diagnostic imaging*; D004867:Equipment Design; D005188:False Negative Reactions; D005189:False Positive Reactions; D005260:Female; D015902:Gamma Cameras; D006801:Humans; D011829:Radiation Dosage; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals; D012680:Sensitivity and Specificity; D017256:Technetium Tc 99m Sestamibi
D019275:Radiopharmaceuticals; D017256:Technetium Tc 99m Sestamibi